News & Updates

Abemaciclib extends survival in metastatic breast cancer

21 Jan 2025

Treatment with abemaciclib, either alone or in combination with fulvestrant, results in improved overall (OS) and progression-free survival (PFS) in patients with HR+/HER2– advanced or metastatic breast cancer, as shown in a recent study.

Abemaciclib extends survival in metastatic breast cancer

21 Jan 2025

Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL

21 Jan 2025 by

In the phase II/III ENRICH trial, first-line (1L) ibrutinib with rituximab (IR) demonstrates superiority over rituximab plus chemotherapy (R-chemo; either R-CHOP* or bendamustine**-R) in older patients with previously untreated mantle cell lymphoma (MCL).

Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL

21 Jan 2025

Fixed-dose albendazole–ivermectin combo shows promise in T. trichiura, hookworm infections

21 Jan 2025

A single-pill combination that contains albendazole and ivermectin is superior to albendazole alone for treating Trichuris trichiura and hookworm infections, with similar safety profiles, according to data from a phase II/III trial.

Fixed-dose albendazole–ivermectin combo shows promise in T. trichiura, hookworm infections

21 Jan 2025

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025 by

Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025

Which TKIs are safe, effective for EGFR-mutated NSCLC?

20 Jan 2025

First-line treatment with erlotinib, gefitinib, and osimertinib demonstrates safety and efficacy in patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), suggests a study.

Which TKIs are safe, effective for EGFR-mutated NSCLC?

20 Jan 2025

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025 by

RO7790121, an antibody against tumour necrosis factor-like ligand 1A (Anti-TL1A), helps improve the health-related quality of life (HR-QoL) for patients with moderately to severely active ulcerative colitis (UC), as shown in the phase IIb TUSCANY-2 trial.

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025

Anti-TNFs may reduce GDM risk in pregnant women with IBD

19 Jan 2025

Pregnant women with inflammatory bowel disease (IBD) who used antitumour necrosis factor (anti-TNF) therapy are at reduced risk of developing gestational diabetes mellitus (GDM), reports a study.

Anti-TNFs may reduce GDM risk in pregnant women with IBD

19 Jan 2025

Hormone therapy poses no glioma risk

19 Jan 2025

Users of hormone therapy do not appear to be at increased risk of glioma, according to a study.

Hormone therapy poses no glioma risk

19 Jan 2025

Twice-yearly depemokimab tied to fewer severe asthma exacerbations

18 Jan 2025

In the treatment of severe asthma with an eosinophilic phenotype, 6-month dosing intervals of depemokimab appears to reduce the rate of exacerbations, as shown in a phase IIIA study.

Twice-yearly depemokimab tied to fewer severe asthma exacerbations

18 Jan 2025

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025 by

Mirikizumab helps improve health-related quality of life (HRQoL) in Crohn’s disease (CD) patients, including those who have not had success with a biologic therapy, according to data from the phase III VIVID-1 study.

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Abemaciclib extends survival in metastatic breast cancer

Abemaciclib extends survival in metastatic breast cancer

Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL

Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL

Fixed-dose albendazole–ivermectin combo shows promise in T. trichiura, hookworm infections

Fixed-dose albendazole–ivermectin combo shows promise in T. trichiura, hookworm infections

No increase in CV risk with JAKi vs TNFi for IBD

No increase in CV risk with JAKi vs TNFi for IBD

Which TKIs are safe, effective for EGFR-mutated NSCLC?

Which TKIs are safe, effective for EGFR-mutated NSCLC?

Novel drug for moderate-to-severe UC yields quality-of-life benefits

Novel drug for moderate-to-severe UC yields quality-of-life benefits

Anti-TNFs may reduce GDM risk in pregnant women with IBD

Anti-TNFs may reduce GDM risk in pregnant women with IBD

Hormone therapy poses no glioma risk

Hormone therapy poses no glioma risk

Twice-yearly depemokimab tied to fewer severe asthma exacerbations

Twice-yearly depemokimab tied to fewer severe asthma exacerbations

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD